On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25. Teva Pharma is an ...

As Teva Pharma prepares for its investor day, investors and market watchers will be closely monitoring the company’s disclosures and Truist’s analysis. In other recent news, Teva Pharmaceutical ...

On Tuesday, Truist Securities began coverage on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), issuing a Buy rating and setting a price target of $25.00.The announcement from ...

The Israel multinational pharma company said the net proceeds from the offerings, together with cash on hand, will be used to fund purchase of its USD 3.150% Senior Notes due 2026, USD 4.750% ...

Teva’s betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management’s $700 million cost-cutting plan is on track, aiming for a 30% operating margin by ...

The move comes as Teva enters the “Acceleration Phase” of its"Pivot to Growth" restructuring strategy the company unveiled in early 2023, CEO Richard Francis said in a statement.

NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw its shares climb 3.7% after the company reported first quarter earnings that beat analyst expectations and raised its full-year guidance.

Teva’s key growth drivers showed strong momentum in the quarter. AUSTEDO revenues jumped 39% YoY to $411 million, while AJOVY sales increased 26% to $139 million. The company’s generics ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...

Teva Pharma to pay $450M to settle kickback, price-fixing allegations By Adrianne Appel 2024-10-11T19:53:00 Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases ...

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.

FTC opens investigation into Teva, escalating patent fight with pharma industry. Democrats have accused drug companies of “junk patent listings,” arguing that the industry is blocking generic ...